{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:02:43Z","timestamp":1784952163297,"version":"3.55.0"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,7,22]]},"DOI":"10.1248\/bpb.b26-00117","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:11:19Z","timestamp":1784671879000},"page":"1125-1131","source":"Crossref","is-referenced-by-count":0,"title":["Population Toxicodynamic Modeling of the Acute Kidney Injury-to-Chronic Kidney Disease Transition Following Repeated Cisplatin Administration in Rats"],"prefix":"10.1248","volume":"49","author":[{"given":"Takumi","family":"Hotta","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650\u20138586, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Muroi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650\u20138586, Japan"},{"name":"Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe 650\u20130047, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruno","family":"Oku","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650\u20138586, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650\u20138586, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Sugioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe 650\u20138586, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. <i>Lung Cancer<\/i>, <b>135<\/b>, 196\u2013204 (2019).","DOI":"10.1016\/j.lungcan.2019.07.010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Li B, Chen L, Luo H-L, Yi F-M, Wei Y-P, Zhang W-X. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: a systematic review and meta-analysis. <i>World J. Clin. Cases<\/i>, <b>7<\/b>, 600\u2013615 (2019).","DOI":"10.12998\/wjcc.v7.i5.600"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. <i>Chem. Res. Toxicol.<\/i>, <b>32<\/b>, 1469\u20131486 (2019).","DOI":"10.1021\/acs.chemrestox.9b00204"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Sato K, Watanabe S, Ohtsubo A, Shoji S, Ishikawa D, Tanaka T, Nozaki K, Kondo R, Okajima M, Miura S, Tanaka J, Sakagami T, Koya T, Kagamu H, Yoshizawa H, Narita I. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. <i>BMC Cancer<\/i>, <b>16<\/b>, 222 (2016).","DOI":"10.1186\/s12885-016-2271-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Faig J, Haughton M, Taylor RC, D\u2019Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. <i>Am. J. Clin. Oncol.<\/i>, <b>41<\/b>, 432\u2013440 (2018).","DOI":"10.1097\/COC.0000000000000301"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. <i>Clin. J. Am. Soc. Nephrol.<\/i>, <b>11<\/b>, 1173\u20131179 (2016).","DOI":"10.2215\/CJN.08070715"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. <i>Kidney Int.<\/i>, <b>73<\/b>, 994\u20131007 (2008).","DOI":"10.1038\/sj.ki.5002786"},{"key":"8","unstructured":"8) Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. <i>Am. J. Cancer Res.<\/i>, <b>10<\/b>, 4151\u20134164 (2020)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Fu Y, Cai J, Li F, Liu Z, Shu S, Wang Y, Liu Y, Tang C, Dong Z. Chronic effects of repeated low-dose cisplatin treatment in mouse kidneys and renal tubular cells. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>317<\/b>, F1582\u2013F1592 (2019).","DOI":"10.1152\/ajprenal.00385.2019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sharp CN, Doll MA, Megyesi J, Oropilla GB, Beverly LJ, Siskind LJ. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>315<\/b>, F161\u2013F172 (2018).","DOI":"10.1152\/ajprenal.00636.2017"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Sharp CN, Doll MA, Dupre TV, Shah PP, Subathra M, Siow D, Arteel GE, Megyesi J, Beverly LJ, Siskind LJ. Repeated administration of low-dose cisplatin in mice induces fibrosis. <i>Am. J. Physiol. Renal Physiol.<\/i>, <b>310<\/b>, F560\u2013F568 (2016).","DOI":"10.1152\/ajprenal.00512.2015"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Fukushima K, Futatsugi A, Maekawa M, Naito S, Okada A, Sugioka N. Comparison of cisplatin-induced nephrotoxicity between single-dose and split-dose administration to rats. <i>Biomed. Pharmacother.<\/i>, <b>147<\/b>, 112619 (2022).","DOI":"10.1016\/j.biopha.2022.112619"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Okada A, Fukushima K, Fujita M, Nakanishi M, Hamori M, Nishimura A, Shibata N, Sugioka N. Alterations in cisplatin pharmacokinetics and its acute\/sub-chronic kidney injury over multiple cycles of cisplatin treatment in rats. <i>Biol. Pharm. Bull.<\/i>, <b>40<\/b>, 1948\u20131955 (2017).","DOI":"10.1248\/bpb.b17-00499"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. <i>Bone Marrow Transplant.<\/i>, <b>48<\/b>, 452\u2013458 (2013).","DOI":"10.1038\/bmt.2012.244"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hu L, Maslanik T, Zerebeckyj M, Plato CF. Evaluation of bioimpedance spectroscopy for the measurement of body fluid compartment volumes in rats. <i>J. Pharmacol. Toxicol. Methods<\/i>, <b>65<\/b>, 75\u201382 (2012).","DOI":"10.1016\/j.vascn.2012.02.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ferrari GO, Ferreira JC, Cavallari RT, Neves KR, dos Reis LM, Dominguez WV, Oliveira EC, Graciolli FG, Passlick-Deetjen J, Jorgetti V, Moys\u00e9s RM. Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5\/6 nephrectomy and adenine models. <i>BMC Nephrol.<\/i>, <b>15<\/b>, 69 (2014).","DOI":"10.1186\/1471-2369-15-69"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, Girard P. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. <i>J. Pharmacokinet. Pharmacodyn.<\/i>, <b>34<\/b>, 57\u201385 (2007).","DOI":"10.1007\/s10928-006-9035-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nagai N, Ogata H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant <i>in vivo<\/i>. <i>Cancer Chemother. Pharmacol.<\/i>, <b>40<\/b>, 11\u201318 (1997).","DOI":"10.1007\/s002800050618"},{"key":"19","unstructured":"19) Thompson LE, Ghimire A, Wen X, Kim C, Choza J, Doherty CL, Buckley BT, Bowles DW, O\u2019Bryant CL, Pfister DG, Jaimes EA, Aleksunes LM, Joy MS. A pharmacokinetic\/toxicodynamic model of cisplatin nephrotoxicity using the kidney injury molecule-1 biomarker. <i>J. Pharmacol. Clin. Toxicol.<\/i>, <b>12<\/b>, 1184 (2024). \u2039https:\/\/pubmed.ncbi.nlm.nih.gov\/39726772\/\u203a"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Xie F, Van Bocxlaer J, Colin P, Carlier C, Van Kerschaver O, Weerts J, Denys H, Tummers P, Willaert W, Ceelen W, Vermeulen A. PKPD modeling and dosing considerations in advanced ovarian cancer patients treated with cisplatin-based intraoperative intraperitoneal chemotherapy. <i>AAPS J.<\/i>, <b>22<\/b>, 96 (2020).","DOI":"10.1208\/s12248-020-00489-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Fukushima K, Okada A, Sasaki K, Kishimoto S, Fukushima S, Hamori M, Nishimura A, Shibata N, Shirai T, Terauchi R, Kubo T, Sugioka N. Population pharmacokinetic-toxicodynamic modeling and simulation of cisplatin-induced acute renal injury in rats: effect of dosing rate on nephrotoxicity. <i>J. Pharm. Sci.<\/i>, <b>105<\/b>, 324\u2013332 (2016).","DOI":"10.1016\/j.xphs.2015.10.022"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Beaubien AR, Karpinski K, Ormsby E. Toxicodynamics and toxicokinetics of amikacin in the guinea pig cochlea. <i>Hear. Res.<\/i>, <b>83<\/b>, 62\u201379 (1995).","DOI":"10.1016\/0378-5955(94)00192-S"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) van Hasselt JGC, Boekhout AH, Beijnen JH, Schellens JHM, Huitema ADR. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. <i>Clin. Pharmacol. Ther.<\/i>, <b>90<\/b>, 126\u2013132 (2011).","DOI":"10.1038\/clpt.2011.74"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. <i>Toxins<\/i>, <b>2<\/b>, 2490\u20132518 (2010).","DOI":"10.3390\/toxins2112490"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Duan Z, Cai G, Li J, Chen X. Cisplatin-induced renal toxicity in elderly people. <i>Ther. Adv. Med. Oncol.<\/i>, <b>12<\/b>, 1758835920923430 (2020).","DOI":"10.1177\/1758835920923430"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Jim\u00e9nez-Triana CA, Castel\u00e1n-Mart\u00ednez OD, Rivas-Ruiz R, Jim\u00e9nez-M\u00e9ndez R, Medina A, Clark P, Rassekh R, Casta\u00f1eda-Hern\u00e1ndez G, Carleton B, Medeiros M. Cisplatin Nephrotoxicity and longitudinal growth in children with solid tumors\u2013A Retrospective Cohort Study. <i>Medicine<\/i>, <b>94<\/b>, e1413 (2015).","DOI":"10.1097\/MD.0000000000001413"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Dikhoff TGMH, De Goeij JJM, Mcvie JG. Long-term body retention and tissue distribution of platinum in cisplatin treated cancer patients. <i>J. Radioanal. Nucl. Chem.<\/i>, <b>236<\/b>, 81\u201386 (1998).","DOI":"10.1007\/BF02386322"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Trevisani F, Di Marco F, Quattrini G, Lepori N, Floris M, Valsecchi D, Giordano L, Dell\u2019Oca I, Cardellini S, Cinque A, Mirabile A. Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer. <i>Front. Oncol.<\/i>, <b>13<\/b>, 1173578 (2023).","DOI":"10.3389\/fonc.2023.1173578"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00117\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:23:05Z","timestamp":1784949785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00117\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00117","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"b26-00117"}}